Navidea Biopharmaceuticals, Inc. (NAVB): Price and Financial Metrics
GET POWR RATINGS... FREE!
NAVB Stock Summary
- The capital turnover (annual revenue relative to shareholder's equity) for NAVB is -4.99 -- better than merely 2.17% of US stocks.
- With a price/sales ratio of 46.17, Navidea Biopharmaceuticals Inc has a higher such ratio than 95.98% of stocks in our set.
- As for revenue growth, note that NAVB's revenue has grown -41.91% over the past 12 months; that beats the revenue growth of only 3.97% of US companies in our set.
- If you're looking for stocks that are quantitatively similar to Navidea Biopharmaceuticals Inc, a group of peers worth examining would be SCYX, MYSZ, ONTX, AEIS, and GEOS.
- Visit NAVB's SEC page to see the company's official filings. To visit the company's web site, go to www.navidea.com.
NAVB Valuation Summary
- In comparison to the median Healthcare stock, NAVB's price/sales ratio is 1394.74% higher, now standing at 56.8.
- NAVB's price/earnings ratio has moved down 11.9 over the prior 243 months.
- NAVB's price/sales ratio has moved up 55.5 over the prior 243 months.
Below are key valuation metrics over time for NAVB.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| NAVB | 2021-08-31 | 56.8 | 8.7 | -4.1 | -3.8 |
| NAVB | 2021-08-30 | 56.8 | 8.7 | -4.1 | -3.8 |
| NAVB | 2021-08-27 | 56.1 | 8.6 | -4.1 | -3.7 |
| NAVB | 2021-08-26 | 55.0 | 8.4 | -4.0 | -3.6 |
| NAVB | 2021-08-25 | 54.0 | 8.3 | -3.9 | -3.6 |
| NAVB | 2021-08-24 | 56.1 | 8.6 | -4.1 | -3.7 |
NAVB Growth Metrics
- Its 3 year net cashflow from operations growth rate is now at 126.25%.
- Its 3 year revenue growth rate is now at -93.51%.
- Its 5 year price growth rate is now at -93.74%.
The table below shows NAVB's growth in key financial areas (numbers in millions of US dollars).
| Date | Revenue | Operating Cash Flow | Net Income to Common Stock |
|---|---|---|---|
| 2021-12-31 | 0.531513 | -10.21815 | -11.73093 |
| 2021-09-30 | 0.700416 | -10.04659 | -11.08244 |
| 2021-06-30 | 0.872423 | -10.66532 | -11.9495 |
| 2021-03-31 | 0.882478 | -10.285 | -11.67886 |
| 2020-12-31 | 0.915013 | -8.173793 | -11.38558 |
| 2020-09-30 | 0.815061 | -8.350325 | -11.15377 |
NAVB Stock Price Chart Interactive Chart >
NAVB Price/Volume Stats
| Current price | $0.77 | 52-week high | $2.19 |
| Prev. close | $0.85 | 52-week low | $0.72 |
| Day low | $0.76 | Volume | 51,900 |
| Day high | $0.90 | Avg. volume | 259,460 |
| 50-day MA | $0.87 | Dividend yield | N/A |
| 200-day MA | $1.19 | Market Cap | 23.38M |
Navidea Biopharmaceuticals, Inc. (NAVB) Company Bio
Navidea Biopharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of precision radiopharmaceutical diagnostics for diseases such as cancer.
Latest NAVB News From Around the Web
Below are the latest news stories about Navidea Biopharmaceuticals Inc that investors may wish to consider to help them evaluate NAVB as an investment opportunity.
Navidea Biopharmaceuticals Announces Research Agreement with the University of Pennsylvania Evaluating Tc99m Tilmanocept as a Prognostic Marker for GlioblastomaDUBLIN, Ohio, February 07, 2022--Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) ("Navidea" or the "Company"), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced the signing of a Sponsored Research Agreement with the University of Pennsylvania ("Penn") for a project to evaluate the use of Tc99m tilmanocept imaging in glioblastoma as a prognostic agent for tumor growth rate and overall survival. The research is led by Principal |
Navidea Biopharmaceuticals Announces Settlement of Platinum Litigation; Receipt of Noncompliance Notice from NYSE AmericanDUBLIN, Ohio, February 03, 2022--Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) ("Navidea" or the "Company"), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced settlement of the ongoing litigation with Platinum-Montaur Life Sciences LLC ("Platinum-Montaur"), an affiliate of Platinum Management (NY) LLC, Platinum Partners Value Arbitrage Fund L.P., Platinum Partners Capital Opportunity Fund, Platinum Partners Liquid Opportuni |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on TuesdayGood morning, trader! |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on WednesdayWe've reached the halfway point of the week and we're starting it with an overview of the biggest pre-market stock movers for Wednesday! |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on ThursdayGood morning, trader! |
NAVB Price Returns
| 1-mo | -25.24% |
| 3-mo | -9.00% |
| 6-mo | -37.40% |
| 1-year | -54.71% |
| 3-year | -40.77% |
| 5-year | -91.44% |
| YTD | -23.00% |
| 2021 | -53.49% |
| 2020 | 70.63% |
| 2019 | -37.00% |
| 2018 | -72.22% |
| 2017 | -43.75% |
Continue Researching NAVB
Here are a few links from around the web to help you further your research on Navidea Biopharmaceuticals Inc's stock as an investment opportunity:Navidea Biopharmaceuticals Inc (NAVB) Stock Price | Nasdaq
Navidea Biopharmaceuticals Inc (NAVB) Stock Quote, History and News - Yahoo Finance
Navidea Biopharmaceuticals Inc (NAVB) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...